文献速递心外重症与机械循环支持

推进耐久性左心室辅助装置植入的质量指标:胸外科医师学会Intermacs数据库分析

Advancing Quality Metrics for Durable Left Ventricular Assist Device Implant: Analysis of the Society of Thoracic Surgeons Intermacs Database.
PubMed 文献 · Ann Thorac Surg · 2022-02-15

基于胸外科医师学会Intermacs数据库2012至2020年160家医院22 173例初次耐久性左心室辅助装置植入患者,评估医院间变异与质量指标一致性。医院观察死亡率中位数7.2%(IQR 5.1%-9.6%),不良事件率各异,手术死亡率O/E比值0.0至6.1,复合结局O/E比值0.28至1.99。结论报告医院间绩效存在显著变异,支持报告医院层面绩效并开展基准比较活动。

要点

  • 160家医院22 173例初次耐久性LVAD植入,观察死亡率中位数7.2%(IQR 5.1%-9.6%)。
  • 主要出血率中位数15.6%(IQR 11.4%-22.4%),呼吸衰竭10.5%(IQR 4.6%-15.7%)。
  • 手术死亡率O/E比值0.0至6.1,复合结局O/E比值0.28至1.99。

核心结论

  • 研究报告植入耐久性LVAD的医院绩效存在显著医院间变异,支持报告医院层面绩效(死亡率、复合结局)并开展基准比较活动以减少不必要的结果变异。

研究设计与样本

  • 基于胸外科医师学会Intermacs数据库的回顾性分析,纳入2012至2020年160家医院22 173例初次耐久性LVAD植入患者,排除植入手术少于10例的医院。

主要发现

  • 观察死亡率中位数7.2%(IQR 5.1%-9.6%),医院间存在变异。
  • 主要出血率中位数15.6%(IQR 11.4%-22.4%),卒中3.1%(IQR 1.6%-4.7%),装置故障2.4%(IQR 0.8%-3.7%),呼吸衰竭10.5%(IQR 4.6%-15.7%),肾功能不全6.4%(IQR 3.2%-9.6%)。
  • 手术死亡率O/E比值范围0.0至6.1,复合结局O/E比值范围0.28至1.99。
  • 医院手术死亡率O/E比值与90天死亡率O/E比值相关性(r=0.74)高于与复合结局O/E比值相关性(r=0.12)。

关键数值与推荐

  • 观察死亡率中位数7.2%(IQR 5.1%-9.6%)。
  • 主要出血率中位数15.6%(IQR 11.4%-22.4%)。
  • 卒中率中位数3.1%(IQR 1.6%-4.7%)。
  • 装置故障率中位数2.4%(IQR 0.8%-3.7%)。
  • 呼吸衰竭率中位数10.5%(IQR 4.6%-15.7%)。

临床怎么用

  • 原文结论支持报告医院层面绩效(死亡率、复合结局)并开展基准比较活动以减少不必要的结果变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients undergoing left ventricular assist device (LVAD) implantation are at risk for death and postoperative adverse outcomes. Interhospital variability and concordance of quality metrics were assessed using the Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). METHODS: A total of 22 173 patients underwent primary, durable LVAD implantation across 160 hospitals from 2012 to 2020, excluding hospitals performing <10 implant procedures. Observed and risk-adjusted operative mortality rates were calculated for each hospital. Outcomes included operative and 90-day mortality, a composite of adverse events (operative mortality, bleeding, stroke, device malfunction, renal dysfunction, respiratory failure), and secondarily failure to rescue. Rates are presented as median (interquartile range [IQR]). Hospital performance was evaluated using observed-to-expected (O/E) ratios for mortality and the composite outcome. RESULTS: Interhospital variability existed in observed (median, 7.2% [IQR, 5.1%-9.6%]) mortality. The rates of adverse events varied across hospitals: major bleeding, 15.6% (IQR, 11.4%-22.4%); stroke, 3.1% (IQR, 1.6%-4.7%); device malfunction, 2.4% (IQR, 0.8%-3.7%); respiratory failure, 10.5% (IQR, 4.6%-15.7%); and renal dysfunction, 6.4% (IQR, 3.2%-9.6%). The O/E ratio for operative mortality varied from 0.0 to 6.1, whereas the O/E ratio for the composite outcome varied from 0.28 to 1.99. Hospital operative mortality O/E ratios were more closely correlated with the 90-day mortality O/E ratio (r = 0.74) than with the composite O/E ratio (r = 0.12). CONCLUSIONS: This study reported substantial interhospital variability in performance for hospitals implanting durable LVADs. These findings support the need to (1) report hospital-level performance (mortality, composite) and (2) undertake benchmarking activities to reduce unwarranted variability in outcomes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Pienta MJ, Wu X, Cascino TM, et al. Advancing Quality Metrics for Durable Left Ventricular Assist Device Implant: Analysis of the Society of Thoracic Surgeons Intermacs Database. Ann Thorac Surg. 2022. PMID: 35176258. doi:10.1016/j.athoracsur.2022.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。